Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Geovax Labs

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies and vaccines against cancers and infectious diseases using a novel vector vaccine platform. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus (HIV), as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GeoVax Labs advances cancer therapies and COVID-19 vaccine development

GeoVax Labs showcased advancements in cancer therapies and COVID-19 vaccine development, underlining a commitment to innovation and global healthcare improvement.
While facing financial challenges due to increased R&D expenses and net loss, GeoVax's strategic strengths in vaccine development and clinical trials offer promising opportunities for growth.
The completion of the Gedeptin trial, ongoing Phase II trials for CM04S1, and plans for future vaccine developments position GeoVax for impactful contributions to healthcare.

GeoVax Labs reports Q2 loss, progresses in key trials

GeoVax's Q2 performance reflects ongoing investment in R&D and progress in key clinical trials.
The company's strengths lie in securing funding, commitment to innovation, and vaccine differentiation.
Challenges include recruitment issues, funding needs, and uncertainties in the pipeline.
Opportunities exist in fundraising, vaccine development, expanding indications, and optimizing clinical trials.

GeoVax Labs reports Q3 progress with vaccine trials and financial challenges

GeoVax Labs' Q3 performance reflects a mix of achievements and challenges, with a focus on advancing vaccine candidates and managing financials. The company's strengths in innovation and clinical trial strategies position it well for future growth opportunities through partnerships and regulatory advancements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Cancer Gene Therapy Program and Next-Generation COVID-19 Vaccine Advancing in Phase 2 Clinical Trials

GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update

Expanded Rights Include Development of GEO-CM04S1 Against Mpox (Monkeypox) and Smallpox ATLANTA, GA, April 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the expansion of its rights under its exclusive license agreement with City of Hope (COH), a world-renowned cancer research and treatment organization, to include development and commercialization rights against orthopoxviruses in addition to SARS-CoV-2. The original license agreement with COH provides GeoVax exclusive worldwide rights to key patents, including the use of COH's proprietary synthetic MVA (sMVA) process, for developing COVID-19 vaccines, including GEO-CM04S1 (CM04S1), a multi-antigenic SARS-CoV-2 investigational vaccine expressing the spike and nucleocapsid antigens of the SARS-CoV-2 virus.

GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses

Atlanta, GA, April 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, presented an update on the development of its SARS-CoV-2 vaccine, GEO-CM04S1, including preliminary data from an ongoing Phase 2 clinical trial, during the 23rd Annual World Vaccine Congress taking place in Washington, DC.

GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate

80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model

GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress

Atlanta, GA, March 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will be represented in two presentations during the upcoming 23rd Annual World Vaccine Congress taking place in Washington, DC on April 3-6, 2023.

GeoVax to Participate at the World Vaccine Congress with Multiple Presentations

GeoVax Labs, Inc. (NASDAQ:GOVX ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Gabrielle DeGravina - CG Capital David Dodd - Chairman, President & CEO Mark Reynolds - CFO Kelly McKee - Chief Medical Officer Mark Newman - Chief Scientific Officer John Sharkey - Head of Business Development Conference Call Participants Jason Kolbert - Dawson James Securities Vernon Bernardino - H.C. Wainwright & Co. Joanne Lee - Maxim Group Robert LeBoyer - Noble Capital Kumar Raja - ROTH Capital Jeffrey Kraws - Crystal Research Associates Operator Good afternoon and welcome everyone to the GeoVax Fourth Quarter and Full Year 2022 Corporate Update Call.

GeoVax Labs, Inc. (GOVX) Q4 2022 Earnings Call Transcript

Company Expands Ongoing Clinical Trials and the Breadth and Capacity of Its Novel Vaccine Platform Technology

GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update

ATLANTA, GA, March 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against solid tumor cancers and infectious diseases, today congratulates its colleague and collaborator, Don Diamond, Ph.D. for recognition as a finalist for the Best Academic/Research Team Award, part of the Vaccine Industry Excellence (ViE) Awards to be held during the World Vaccine Congress in Washington, DC on April 3-6, 2023.

GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress

ATLANTA, GA, March 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report 2022 financial results on Thursday, March 23, 2023 after the market closes.

GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update

ATLANTA, GA, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, will discuss the company's progress with Senior Research Analyst Kumaragura Raja, Ph.D. from ROTH MKM. The discussion will take place during a fireside chat at the 35th Annual Roth Conference in Dana Point, CA being held March 12-14, 2023.

GeoVax to Participate at the 35th Annual Roth Conference

Data Presented Indicated Very High Levels of Immunogenicity of the Combinational Therapy

GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections

ATLANTA, GA, Feb. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, and EmVenio Research, a patient-focused decentralized trial global organization, today announced a collaboration to deploy a mobile clinical facility in the Claremont, California area to expand GeoVax's ongoing Phase 2 clinical trial evaluating GEO-CM04S1 as a COVID-19 booster vaccine in healthy patients.

GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial

Creative Medical Technology Holdings

NeuroSense Therapeutics Ltd

Quantum Computing

Zhongchao

Stock Market News Has These Penny Stocks On Traders' Watch Lists This Week. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 5 To Watch After News This Week

ATLANTA, GA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced significant progress in developing a high-yield, high-capacity, continuous avian cell line system for manufacturing its MVA (modified vaccinia Ankara)-based vaccines and immunotherapies.

GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines

ATLANTA, GA, Feb. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today its clinical trial of Gedeptin® for patients with recurrent head and neck cancers is now actively enrolling patients at three major research centers -- Stanford University, Emory University and Thomas Jefferson University.

GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers

ATLANTA, GA, Jan. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 2023 BIO CEO & Investor Conference taking place in-person in New York City at the New York Marriott Marquis and virtually on February 6-9, 2023.

GeoVax to Present at the 2023 BIO CEO & Investor Conference

Novo Integrated Sciences, Inc.

Sonoma Pharmaceuticals

Are penny stocks worth investing in? The post Why Investing in Penny Stocks Could Be Worth It appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why Investing in Penny Stocks Could Be Worth It

Shares of GeoVax (NASDAQ: GOVX ) are shooting to the top of today's trending ticker list. That's as GOVX stock is higher by about 60% so far on Wednesday.

Why Is GeoVax (NASDAQ:GOVX) Stock Up 80% Today?

ATLANTA, GA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that the U.S. Patent and Trademark Office issued a Notice of Allowance for Patent Application No. 17/000,768 titled, “Method for Generating a ZIKV Immune Response Utilizing a Recombinant Modified Vaccinia Ankara Vector Encoding the NS1 Protein.”

GeoVax Receives Notice of Allowance for Zika Vaccine Patent

ATLANTA, GA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that it will present at the Biotech Showcase coinciding with the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, January 9-12, 2023.

GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023

ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School of Medicine President and CEO, as Special Advisor to the Chairman/CEO and Board of Directors of GeoVax.

Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax

Allarity Therapeutics

Applied UV

Understand these tips for investing in penny stocks The post The Do's and Don'ts of Penny Stocks Investing for New Investors  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

The Do's and Don'ts of Penny Stocks Investing for New Investors

Dr. Morgan Brings Extensive COVID-19, Medical and Healthcare Management Expertise

GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today announced that Mark J. Newman, Ph.D., Chief Scientific Officer of GeoVax, will present at the World Vaccine & Immunotherapy Congress (WVIC) West Coast 2022, taking place November 28-December 1, 2022, in San Diego, California.

GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022

GeoVax Labs, Inc. (NASDAQ:GOVX ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Gabrielle DeGravina - CG Capital David Dodd - Chairman, President and Chief Executive Officer Mark Reynolds - Chief Financial Officer Mark Newman - Chief Scientific Officer John Sharkey - Head, Business Development Kelly McKee - Chief Medical Officer Conference Call Participants Jeffrey Kraws - Crystal Research Associates Robert LeBoyer - Noble Capital Operator Good afternoon and welcome everyone to the GeoVax Third Quarter 2022 Corporate Update Call. My name is Ralph and I will facilitate today's call.

News for Geovax Labs Stock (GOVX)